On June 8, 2020 Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, reported the appointment of Jason O’Neill as chief executive officer, effective June 1, 2020 (Press release, Dendreon, JUN 8, 2020, View Source [SID1234560905]). O’Neill brings extensive pharmaceutical leadership experience to Dendreon, with prominent roles in the areas of general management, commercial development and marketing in the United States and Asia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The opportunity to join Dendreon at this critical stage in the company’s growth is exciting," said O’Neill, chief executive officer of Dendreon. "My experience developing successful growth and market entry strategies is a timely addition to the company as we work to build a robust R&D pipeline and expand access to the life-extending benefits of PROVENGE (sipuleucel-T) in the United States and internationally."
O’Neill was previously responsible for leading Sanofi’s oncology portfolio during six of his nine years with the company. That portfolio included Taxotere (docetaxel), the most widely prescribed chemotherapy in the metastatic prostate cancer setting.
He also recently served as chief executive officer at Iridium Therapeutics, a pre-clinical stage pharmaceutical company focused on maximizing the benefits of proven therapies by improving their delivery and adherence. Iridium’s lead candidates were 3- and 6-month injectable formulations of anastrozole, the leading hormone treatment for postmenopausal women with hormone receptor positive breast cancer.
He has also held a variety of general management and senior new product development roles throughout his career at major pharmaceutical companies including Roche/Genentech, Mallinckrodt, Bristol-Myers Squibb and Pfizer. His experience in the Asia Pacific market will contribute to Dendreon’s long-term strategy of growing into a multi-product, multi-market company.
O’Neill holds a Bachelor of Arts degree from Yale University and a Master of Business Administration from the Kellogg School of Management at Northwestern University.